Eupraxia Pharmaceuticals Inc.
EPRX
$5.96
-$0.03-0.50%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -87.11% | -122.55% | -7.03% | -45.51% | -11.91% |
| Total Depreciation and Amortization | 93.76% | 33.58% | 66.67% | 31.90% | 24.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -127.22% | 681.99% | -80.07% | 65.73% | 472.61% |
| Change in Net Operating Assets | 496.25% | -140.72% | 135.90% | 48.12% | -382.85% |
| Cash from Operations | -69.02% | -62.87% | 55.77% | -8.05% | 2.18% |
| Capital Expenditure | -93.49% | -336.34% | -42.79% | -1,438.89% | -2,385.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -47,267.75% | -341.32% | -42.79% | -1,038.98% | -2,385.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 15,853.24% | -95.30% | -- | -- | -98.15% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 15,853.24% | -95.30% | 1,706.02% | 105.31% | -98.14% |
| Foreign Exchange rate Adjustments | -569.32% | 102.66% | -176.75% | 239.01% | 120.72% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -290.73% | -134.35% | 572.17% | 38.93% | -134.09% |